We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Incanthera Plc (INC) ORD GBP0.0002

Sell:13.00p Buy:14.00p Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:13.00p
Buy:14.00p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:13.00p
Buy:14.00p
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Incanthera plc is a United Kingdom-based dermatology and oncology therapeutics company. The Company is focused on drug discovery and the development of targeted medicines for the treatment of cancer. Its lead product is Sol, a topical product developed for the treatment of solar keratosis and the prevention of skin cancers. Its pipeline of drug candidates includes Sol, EP0015, Equin and Duo-C. EP0015 targets the treatment of adult solid cancers remains palliative rather than curative and represents an unmet need. Equin is a quinone-based prodrug activated by the enzyme DT-diaphorase, which itself is over-expressed in many solid tumors, including breast, colon, liver, bladder, stomach, central nervous system, lung tumors and melanomas. Duo-C focuses on targeting colorectal cancer using duocarmycins, which are recognized for their extreme cytotoxicity, converted to a prodrug and designed to overcome their intrinsic toxicity and make them manageable and useful in the clinical setup.

Contact details

Address:
76 King Street
MANCHESTER
M2 4NH
United Kingdom
Telephone:
+44 (0161) 8175005
Website:
www.incanthera.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

EPIC:
INC
ISIN:
GB00BGL7YW15
Market cap:
£12.67 million
Shares in issue:
77.82 million
Sector:
No specific industry
Exchange:
-
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Timothy Mccarthy
    Executive Chairman
  • Simon Ward
    Chief Executive Officer, Director
  • Laura Brogden
    Chief Financial Officer
  • Suzanne Brocks
    Head of Communications and Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.